Negotiating Health: Intellectual Property and Access to MedicinesPedro Roffe, Geoff Tansey Taylor & Francis, 27. 4. 2012. - 320 страница In developing countries, access to affordable medicines for the treatment of diseases such as AIDS and malaria remains a matter of life or death. In Africa, for instance, more than one million children die each year from malaria alone, a figure which could soon be far higher with the extension of patent rules for pharmaceuticals. Previously, access to essential medicines was made possible by the supply of much cheaper generics, manufactured largely by India; from 2005, however, the availability of these drugs is threatened as new WTO rules take effect. Halting the spread of malaria and HIV/AIDS is one of the eight Millennium Goals adopted at the UN Millennium Summit, which makes this a timely and topical book. Informed analysis is provided by internationally renowned contributors who look at the post-2005 world and discuss how action may be taken to ensure that intellectual property regimes are interpreted and implemented in a manner supportive to the right to protect public health and, in particular, to promote access to medicines for all. |
Садржај
1 | |
6 | |
Access Control Beyond Patents to Data | 79 |
Ways Forward in Promoting Access | 179 |
The Doha Declaration on the TRIPS Agreement and Public Health | 268 |
The 30 August Decision on the Implementation of Paragraph 6 of the Doha Declaration and the General Councils Chairpersons Statement ... | 271 |
279 | |
297 | |
Друга издања - Прикажи све
Negotiating Health: Intellectual Property and Access to Medicines Pedro Roffe,Geoff Tansey,David Vivas Eugui Приказ није доступан - 2006 |
Negotiating Health: Intellectual Property and Access to Medicines Pedro Roffe,Geoff Tansey,David Vivas Eugui Приказ није доступан - 2006 |
Чести термини и фразе
30 August abuse access to medicines Agreement and Public anti-competitive practices anti-trust application Arbitration authorities bioequivalence CAFTA Chapter chemical entities clinical trials compensation competition policy compulsory licence cost-sharing approach costs data exclusivity data submitted Decision developing countries diseases Doha Declaration domestic drugs economic effective ensure essential medicines example exclusive rights exporting firms Free Trade Agreement FTAs GlaxoSmithKline global granted HIV/AIDS implementation important innovation intellectual property rights investment IPRs issues legislation market exclusivity ment NAFTA negotiations ofthe original paragraph Paris Convention partnerships Party patent holder patent pool patent protection PDPs period Pharma pharmaceutical companies pharmaceutical industry pharmaceutical products pharmaceutical sector potential product development public health registration data regulatory relevant rely TB Alliance term test data tion trade secrets TRIPS Agreement UNCTAD undisclosed data undisclosed test unfair commercial USTR vaccines WIPO World Trade Organization WTO Members